WallStSmart

Natera Inc (NTRA)vsWaters Corporation (WAT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Waters Corporation generates 51% more annual revenue ($3.77B vs $2.50B). WAT leads profitability with a 11.9% profit margin vs -9.1%. WAT earns a higher WallStSmart Score of 50/100 (C-).

NTRA

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.0
Piotroski: 3/9Altman Z: 0.82

WAT

Buy

50

out of 100

Grade: C-

Growth: 5.3Profit: 5.0Value: 3.3Quality: 7.0
Piotroski: 2/9Altman Z: 4.85
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for NTRA.

WATSignificantly Overvalued (-81.9%)

Margin of Safety

-81.9%

Fair Value

$180.97

Current Price

$396.08

$215.11 premium

UndervaluedFair: $180.97Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NTRA2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
38.8%10/10

Revenue surging 38.8% year-over-year

Debt/EquityHealth
0.149/10

Conservative balance sheet, low leverage

WAT3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
91.4%10/10

Revenue surging 91.4% year-over-year

Altman Z-ScoreHealth
4.8510/10

Safe zone — low bankruptcy risk

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Areas to Watch

NTRA4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
22.1x2/10

Trading at 22.1x book value

Return on EquityProfitability
-12.8%2/10

ROE of -12.8% — below average capital efficiency

WAT4 concerns · Avg: 3.3/10
PEG RatioValuation
1.694/10

Expensive relative to growth rate

Return on EquityProfitability
2.9%3/10

ROE of 2.9% — below average capital efficiency

Operating MarginProfitability
2.8%3/10

Operating margin of 2.8%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : NTRA

The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 38.8% demonstrates continued momentum.

Bull Case : WAT

The strongest argument for WAT centers on Revenue Growth, Altman Z-Score, Price/Book. Revenue growth of 91.4% demonstrates continued momentum.

Bear Case : NTRA

The primary concerns for NTRA are EPS Growth, Piotroski F-Score, Price/Book.

Bear Case : WAT

The primary concerns for WAT are PEG Ratio, Return on Equity, Operating Margin. A P/E of 48.1x leaves little room for execution misses.

Key Dynamics to Monitor

NTRA profiles as a hypergrowth stock while WAT is a growth play — different risk/reward profiles.

NTRA carries more volatility with a beta of 1.50 — expect wider price swings.

WAT is growing revenue faster at 91.4% — sustainability is the question.

NTRA generates stronger free cash flow (18M), providing more financial flexibility.

Bottom Line

WAT scores higher overall (50/100 vs 31/100) and 91.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Natera Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.

Waters Corporation

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.

Want to dig deeper into these stocks?